These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 10223578)

  • 1. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
    Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
    Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
    Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
    Miyata Y; Kanda S; Sakai H; Hakariya T; Kanetake H
    Urology; 2005 Jun; 65(6):1238-43. PubMed ID: 15922418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone therapy in advanced prostate cancer.
    Forster TH; Stoffel F; Gasser TC
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
    Pu XY; Wang XH; Wu YL; Wang HP
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.
    Oh WK
    Urol Oncol; 2003; 21(3):229-34. PubMed ID: 12810211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B
    Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of neoadjuvant therapy for prostate cancer].
    Okada K; Hachiya T
    Nihon Hinyokika Gakkai Zasshi; 1997 Sep; 88(9):769-77. PubMed ID: 9364842
    [No Abstract]   [Full Text] [Related]  

  • 15. Neoadjuvant hormonal therapy: the Canadian experience.
    Labrie F; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M; Tetu B; Fradet Y; Bélanger A; Candas B
    Urology; 1997 Mar; 49(3A Suppl):56-64. PubMed ID: 9123738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant hormonal deprivation before radical prostatectomy.
    Schulman CC; Sassine AM
    Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ; Small EJ
    Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.